Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply
JAMA
.
2017 Sep 19;318(11):1067-1068.
doi: 10.1001/jama.2017.11517.
Authors
Nicholas S Downing
1
,
Nilay D Shah
2
,
Joseph S Ross
3
Affiliations
1
Brigham and Women's Hospital, Boston, Massachusetts.
2
Mayo Clinic, Rochester, Minnesota.
3
Yale University School of Medicine, New Haven, Connecticut.
PMID:
28975302
DOI:
10.1001/jama.2017.11517
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Product Surveillance, Postmarketing*
Safety
United States
United States Food and Drug Administration*